Online Trial Tracker - Larvol Sigma

Autoimmune Diseases

Lemtrada (alemtuzumab)

Phase 3

Welcome, Profile Billing Logout

4 Trials

All TrialsPhase 3

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lemtrada (alemtuzumab) / Sanofi

CARE-MS I, NCT00530348 / 2007-001161-14 / ACTRN12608000435381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

	CARE-MS I trial
	Nov 2015 - Nov 2015: CARE-MS I trial
	ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
	Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS I extension)
	CARE-MS I & CARE-MS II
	Apr 2015 - Apr 2015: CARE-MS I & CARE-MS II
	CONy 2015: Multiple sclerosis (CARE MS I)
	Feb 2015 - Feb 2015: CONy 2015: Multiple sclerosis (CARE MS I)
	ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	ACTRIMS-ECTRIMS 2014: MS (CARE-MS I)
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (CARE-MS I)
	ACTRIMS 2014: MS
	Jun 2014 - Jun 2014: ACTRIMS 2014: MS
	AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
	Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
	CARE-MS I
	Oct 2013 - Oct 2013: CARE-MS I
	ECTRIMS 2013: Multiple sclerosis (CARE-MS I)
	Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis (CARE-MS I)
	WCN 2013: Multiple sclerosis (CARE MS-I)
	Jul 2013 - Jul 2013: WCN 2013: Multiple sclerosis (CARE MS-I)
	CARE-MS I, CARE-MS II
	Mar 2013 - Mar 2013: CARE-MS I, CARE-MS II
	P3 data: CARE MS I
	Oct 2012 - Oct 2012: P3 data: CARE MS I
	Data - ACTRIMS 2012
	Jun 2012 - Jun 2012: Data - ACTRIMS 2012
	Data
	Apr 2012 - Apr 2012: Data
	Data AAN (MS)
	Mar 2012 - Mar 2012: Data AAN (MS)
	Data, MS
	Oct 2011 - Oct 2011: Data, MS
	Data ECTRIMS, MS
	Oct 2011 - Oct 2011: Data ECTRIMS, MS
	Data, MS
	Jul 2011 - Jul 2011: Data, MS
	Data, MS
	Jul 2011 - Jul 2011: Data, MS
More

Completed

581

US, Canada, Europe, RoW

Alemtuzumab, Lemtrada, Interferon beta-1a, Rebif®

Genzyme, a Sanofi Company, Bayer

Multiple Sclerosis, Relapsing-Remitting

04/11

CARE-MS II, NCT00548405 / 2007-001162-32 / ACTRN12608000426381: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

	AAN 2016: CARE-MS II
	Mar 2016 - Mar 2016: AAN 2016: CARE-MS II
	ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
	Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (CARE-MS II)
	CMSC 2015
	Jun 2015 - Jun 2015: CMSC 2015
	CMSC 2015
	Jun 2015 - Jun 2015: CMSC 2015
	CARE-MS I & CARE-MS II
	Apr 2015 - Apr 2015: CARE-MS I & CARE-MS II
	AAN 2015: Multiple sclerosis (CARE MS-II)
	Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (CARE MS-II)
	ACTRIMS-ECTRIMS 2014: MS (CARE-MS II)
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (CARE-MS II)
	ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	ACTRIMS 2014: MS
	Jun 2014 - Jun 2014: ACTRIMS 2014: MS
	EFNS-ENS 2014: MS (CARE MS-II)
	May 2014 - May 2014: EFNS-ENS 2014: MS (CARE MS-II)
	CONy 2014: Multiple sclerosis (CARE MS-II)
	May 2014 - May 2014: CONy 2014: Multiple sclerosis (CARE MS-II)
	AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
	Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
	AAN 2014: Multiple sclerosis (CARE II)
	Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CARE II)
	ECTRIMS 2013: Multiple sclerosis (CARE-MS II)
	Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis (CARE-MS II)
	CMSC-ACTRIMS 2013: Multiple sclerosis (CARE-MS II)
	Jun 2013 - Jun 2013: CMSC-ACTRIMS 2013: Multiple sclerosis (CARE-MS II)
	ENS 2013: Multiple sclerosis (CARE-MS II)
	May 2013 - May 2013: ENS 2013: Multiple sclerosis (CARE-MS II)
	CARE-MS I, CARE-MS II
	Mar 2013 - Mar 2013: CARE-MS I, CARE-MS II
	AAN 2013
	Jan 2013 - Jan 2013: AAN 2013
	P3 data: CARE MS II
	Oct 2012 - Oct 2012: P3 data: CARE MS II
	Data (CARE MS II EFNS)
	Aug 2012 - Aug 2012: Data (CARE MS II EFNS)
	Data (MS, CARE MS II)
	Jun 2012 - Jun 2012: Data (MS, CARE MS II)
	Data - ACTRIMS 2012
	Jun 2012 - Jun 2012: Data - ACTRIMS 2012
	Data
	Apr 2012 - Apr 2012: Data
	Data, MS
	Nov 2011 - Nov 2011: Data, MS
More

Completed

840

US, Canada, Europe, RoW

Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg, Interferon beta-1a, Rebif®

Genzyme, a Sanofi Company, Bayer

Multiple Sclerosis, Relapsing-Remitting

09/11

NCT00930553 / 2009-010788-18: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

	CMSC 2016
	Jun 2016 - Jun 2016: CMSC 2016
	EAN 2016
	Jun 2016 - Jun 2016: EAN 2016
	AAN 2016: CARE-MS II extension
	Mar 2016 - Mar 2016: AAN 2016: CARE-MS II extension
	CONY 2016: MS
	Mar 2016 - Mar 2016: CONY 2016: MS
	CMSC 2015
	Jun 2015 - Jun 2015: CMSC 2015
	CMSC 2015
	Jun 2015 - Jun 2015: CMSC 2015
	EAN 2015
	Jun 2015 - Jun 2015: EAN 2015
	AAN 2015: Multiple sclerosis (CARE MS I)
	Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (CARE MS I)
	CONy 2015: Multiple sclerosis
	Feb 2015 - Feb 2015: CONy 2015: Multiple sclerosis

	Sep 2014 - Sep 2014:
	ACTRIMS-ECTRIMS 2014: MS
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS
	ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (CARE-MS I; CARE-MS II)
	EFNS-ENS 2014: MS (CARE MS-I)
	May 2014 - May 2014: EFNS-ENS 2014: MS (CARE MS-I)

	Apr 2014 - Apr 2014:
	AAN 2014: Multiple sclerosis
	Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis

	Mar 2013 - Mar 2013:
More

Completed

1314

US, Canada, Europe, RoW

alemtuzumab

Genzyme, a Sanofi Company, Bayer

Multiple Sclerosis, Relapsing-Remitting

02/16

iCAMMS-IST, NCT01307332: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

Completed

Canada

MabCampath-1h, Alemtuzumab

University of British Columbia, Genzyme, a Sanofi Company

Relapsing Remitting Multiple Sclerosis

09/18

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites